Publications from OUS - Cell Signaling and Immune Regulation (Kjetil Taskén)

72 publications found

Publications 2025

1. Arseni L, Sigismondo G, Yazdanparast H, Hermansen JU, Mack N, Ohl S, Kalter V, Iskar M, Kalxdorf M, Friedel D, Rettel M, Paul Y, Ringshausen I, Eldering E, Dubois J, Kater AP, Zapatka M, Roessner PM, Tausch E, Stilgenbauer S, Dietrich S, Savitski MM, Skånland SS, Krijgsveld J, Lichter P et al. (2025)
   Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL
   Nat Commun, 16 (1), 1041
   DOI 10.1038/s41467-025-56318-7, PubMed 39863584
2. García-Díaz N, Solli E, Hajjar E, Cornillot-Clément S, Landskron J, Ahmad R, Wei Q, Taskén K (2025)
   MAPK and STAT3 Inhibitors Modulate FoxP3 Expression and Regulatory T Cell Function
   Eur J Immunol, 55 (2), e202451225
   DOI 10.1002/eji.202451225, PubMed 39955647
3. Kelly MP, Nikolaev VO, Gobejishvili L, Lugnier C, Hesslinger C, Nickolaus P, Kass DA, Pereira de Vasconcelos W, Fischmeister R, Brocke S, Epstein PM, Piazza GA, Keeton AB, Zhou G, Abdel-Halim M, Abadi AH, Baillie GS, Giembycz MA, Bolger G, Snyder G, Tasken K, Saidu NEB, Schmidt M, Zaccolo M, Schermuly RT et al. (2025)
   Cyclic nucleotide phosphodiesterases as drug targets
   Pharmacol Rev, 77 (3), 100042 (in press)
   DOI 10.1016/j.pharmr.2025.100042, PubMed 40081105
4. Posadas-Cantera S, Mitsuiki N, Emmerich F, Patiño V, Lorenz HM, Neth O, Dybedal I, Taskén K, Schäffer AA, Grimbacher B, Gámez-Díaz L (2025)
   The effect of HLA genotype on disease onset and severity in CTLA-4 insufficiency
   Front Immunol, 15, 1447995
   DOI 10.3389/fimmu.2024.1447995, PubMed 39835139
5. Taskén K, Mahon P (2025)
   Accelerating precision oncology by converging pragmatic trials and real-world evidence
   Nat Rev Drug Discov (in press)
   DOI 10.1038/d41573-025-00047-5, PubMed 40082591
   
6. Wei Q, Foyn H, Landskron J, Wang S, Rye IH, Skånland SS, Russnes HEG, Klaveness J, Ahmad R, Taskén K (2025)
   Identification of a group of 9-amino-acridines that selectively downregulate regulatory T cell functions through FoxP3
   iScience, 28 (3), 111931
   DOI 10.1016/j.isci.2025.111931, PubMed 40034859
7. Yin Y, Xu H, He L, Brown JR, Mato AR, Aittokallio T, Skånland SS (2025)
   Protein profiles predict treatment responses to the PI3K inhibitor umbralisib in patients with chronic lymphocytic leukemia
   Clin Cancer Res (in press)
   DOI 10.1158/1078-0432.CCR-24-2911, PubMed 40085050

Publications 2024

1. Bischof K, Cremaschi A, Eroukhmanoff L, Landskron J, Flage-Larsen LL, Gade A, Bjørge L, Urbanucci A, Taskén K (2024)
   Patient-derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways
   Mol Oncol, 19 (1), 81-98
   DOI 10.1002/1878-0261.13726, PubMed 39245677
2. Bjørgo E, Fagereng GL, Russnes HG, Smeland S, Taskén K, Helland Å (2024)
   Acta Oncologica Nordic Precision Cancer Medicine Symposium 2023 - merging clinical research and standard healthcare
   Acta Oncol, 63, 487-490
   DOI 10.2340/1651-226X.2024.24954, PubMed 38910311
3. Gregersen I, Kong XY, Kooijman S, Foyn H, Grannes H, Olsen MB, Lone AM, Yang K, Quiles-Jiménez A, Tran M, Øgaard J, Segers FM, Rashidi A, Sagen EL, Lauritzen KH, Pronk ACM, de Boer JF, Holven KB, Melum E, Aukrust P, Taskén K, Holm S, Rensen PCN, Dahl TB, Halvorsen B (2024)
   T cells with increased responsiveness cause obesity in mice without diet intervention
   iScience, 27 (4), 109471
   DOI 10.1016/j.isci.2024.109471, PubMed 38551005
4. Helland Å, Steinskog ESS, Blix ES, Flobak Å, Brabrand S, Puco K, Niehusmann P, Meltzer S, Oppedal IA, Haug Å, Torkildsen CF, Randen U, Gilje B, Lønning PE, Gjertsen BT, Hovland R, Russnes HG, Fagereng GL, Smeland S, Tasken K (2024)
   [Raising the quality of cancer treatment]
   Tidsskr Nor Laegeforen, 144 (1)
   DOI 10.4045/tidsskr.23.0740, PubMed 38258713
5. Hermansen JU, Yin Y, Rein ID, Skånland SS (2024)
   Immunophenotyping with (phospho)protein profiling and fluorescent cell barcoding for single-cell signaling analysis and biomarker discovery
   NPJ Precis Oncol, 8 (1), 107
   DOI 10.1038/s41698-024-00604-y, PubMed 38769096
6. Kempkes RWM, Nikolaou C, Nabhan M, Saidu NEB (2024)
   IUIS 2023: yEFIS workshop on career development and code-switching
   Eur J Immunol, 54 (7), e2451155
   DOI 10.1002/eji.202451155, PubMed 38676471
7. Montoya S, Bourcier J, Noviski M, Lu H, Thompson MC, Chirino A, Jahn J, Sondhi AK, Gajewski S, Tan YSM, Yung S, Urban A, Wang E, Han C, Mi X, Kim WJ, Sievers Q, Auger P, Bousquet H, Brathaban N, Bravo B, Gessner M, Guiducci C, Iuliano JN, Kane T et al. (2024)
   Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
   Science, 383 (6682), eadi5798
   DOI 10.1126/science.adi5798, PubMed 38301010
8. Puco K, Fagereng GL, Brabrand S, Niehusmann P, Støre Blix E, Samdal Steinskog ES, Haug Å, Fredvik Torkildsen C, Oppedal IA, Meltzer S, Flobak Å, Johansson KAM, Bjørge L, Hjortland GO, Dalhaug A, Lund JÅ, Gilje B, Grønlie Cameron M, Hovland R, Falk RS, Smeland S, Giercksky Russnes HE, Taskén K, Helland Å, InPreD Consortium et al. (2024)
   IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results
   Acta Oncol, 63, 379-384
   DOI 10.2340/1651-226X.2024.28322, PubMed 38779911
9. Skånland SS, Okkenhaug K, Davids MS (2024)
   PI3K Inhibitors in Hematology: When One Door Closes…
   Clin Cancer Res, 30 (17), 3667-3675
   DOI 10.1158/1078-0432.CCR-24-0967, PubMed 38967552
10. Sveen A, Johannessen B, Klokkerud SM, Kraggerud SM, Meza-Zepeda LA, Bjørnslett M, Bischof K, Myklebost O, Taskén K, Skotheim RI, Dørum A, Davidson B, Lothe RA (2024)
    Evolutionary mode and timing of dissemination of high-grade serous carcinomas
    JCI Insight, 9 (3)
    DOI 10.1172/jci.insight.170423, PubMed 38175731
11. Taskén K, F Haj Mohammad S, Fagereng GL, Sørum Falk R, Helland Å, Barjesteh van Waalwijk van Doorn-Khosrovani S, Steen Carlsson K, Ryll B, Jalkanen K, Edsjö A, Russnes HG, Lassen U, Hallersjö Hult E, Lugowska I, Blay JY, Verlingue L, Abel E, Lowery MA, Krebs MG, Staal Rohrberg K, Ojamaa K, Oliveira J, Verheul HMW, Voest EE, Gelderblom H et al. (2024)
    PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe
    Acta Oncol, 63, 385-391
    DOI 10.2340/1651-226X.2024.34791, PubMed 38779910

Publications 2023

1. Andersen AN, Brodersen AM, Ayuda-Durán P, Piechaczyk L, Tadele DS, Baken L, Fredriksen J, Stoksflod M, Lenartova A, Fløisand Y, Skånland SS, Enserink JM (2023)
   Clinical forecasting of acute myeloid leukemia using ex vivo drug-sensitivity profiling
   Cell Rep Methods, 3 (12), 100654
   DOI 10.1016/j.crmeth.2023.100654, PubMed 38065095
2. Ayuda-Durán P, Hermansen JU, Giliberto M, Yin Y, Hanes R, Gordon S, Kuusanmäki H, Brodersen AM, Andersen AN, Taskén K, Wennerberg K, Enserink JM, Skånland SS (2023)
   Standardized assays to monitor drug sensitivity in hematologic cancers
   Cell Death Discov, 9 (1), 435
   DOI 10.1038/s41420-023-01722-5, PubMed 38040674
3. García-Díaz N, Wei Q, Taskén K (2023)
   Small molecule inhibitors targeting regulatory T cells for cancer treatment
   Eur J Immunol, 54 (2), e2350448
   DOI 10.1002/eji.202350448, PubMed 37937687
4. Hermansen JU, Yin Y, Urban A, Myklebust CV, Karlsen L, Melvold K, Tveita AA, Taskén K, Munthe LA, Tjønnfjord GE, Skånland SS (2023)
   A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine
   Cell Death Discov, 9 (1), 125
   DOI 10.1038/s41420-023-01426-w, PubMed 37055391
5. Köhn-Luque A, Myklebust EM, Tadele DS, Giliberto M, Schmiester L, Noory J, Harivel E, Arsenteva P, Mumenthaler SM, Schjesvold F, Taskén K, Enserink JM, Leder K, Frigessi A, Foo J (2023)
   Phenotypic deconvolution in heterogeneous cancer cell populations using drug-screening data
   Cell Rep Methods, 3 (3), 100417
   DOI 10.1016/j.crmeth.2023.100417, PubMed 37056380
6. Le Tourneau C, André F, Helland Å, Mileshkin L, Minnaard W, Schiel A, Taskén K, Thomas DM, Veronese ML, Durán-Pacheco G, Leyens L, Rufibach K, Thomas M, Krämer A (2023)
   Modified study designs to expand treatment options in personalised oncology: a multistakeholder view
   Eur J Cancer, 194, 113278
   DOI 10.1016/j.ejca.2023.113278, PubMed 37820553
7. Skogestad J, Albert I, Hougen K, Lothe GB, Lunde M, Eken OS, Veras I, Huynh NTT, Børstad M, Marshall S, Shen X, Louch WE, Robinson EL, Cleveland JC, Ambardekar AV, Schwisow JA, Jonas E, Calejo AI, Morth JP, Taskén K, Melleby AO, Lunde PK, Sjaastad I, Carlson CR, Aronsen JM (2023)
   Disruption of Phosphodiesterase 3A Binding to SERCA2 Increases SERCA2 Activity and Reduces Mortality in Mice With Chronic Heart Failure
   Circulation, 147 (16), 1221-1236
   DOI 10.1161/CIRCULATIONAHA.121.054168, PubMed 36876489
8. Skånland SS, Brown JR (2023)
   PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?
   Haematologica, 108 (1), 9-21
   DOI 10.3324/haematol.2022.281266, PubMed 35899388
9. Spasevska I, Sharma A, Steen CB, Josefsson SE, Blaker YN, Kolstad A, Rustad EH, Meyer S, Isaksen K, Chellappa S, Kushekhar K, Beiske K, Førsund MS, Spetalen S, Holte H, Østenstad B, Brodtkorb M, Kimby E, Olweus J, Taskén K, Newman AM, Lorenz S, Smeland EB, Alizadeh AA, Huse K et al. (2023)
   Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma
   Blood Adv, 7 (23), 7216-7230
   DOI 10.1182/bloodadvances.2023010158, PubMed 37695745
10. Zhang D, Harris HM, Chen J, Judy J, James G, Kelly A, McIntosh J, Tenn-McClellan A, Ambing E, Tan YS, Lu H, Gajewski S, Clifton MC, Yung S, Robbins DW, Pirooznia M, Skånland SS, Gaglione E, Mhibik M, Underbayev C, Ahn IE, Sun C, Herman SEM, Noviski M, Wiestner A (2023)
    NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts
    Blood, 141 (13), 1584-1596
    DOI 10.1182/blood.2022016934, PubMed 36375120

Publications 2022

1. Aronson JH, Skånland SS, Roeker LE, Thompson MC, Mato AR (2022)
   Approach to a patient with "double refractory" chronic lymphocytic leukemia: "Double, double toil and trouble" (Shakespeare)
   Am J Hematol, 97 Suppl 2, S19-S25
   DOI 10.1002/ajh.26682, PubMed 36125036
2. Athanasiadis P, Ianevski A, Skånland SS, Aittokallio T (2022)
   Computational Pipeline for Rational Drug Combination Screening in Patient-Derived Cells
   Methods Mol Biol, 2449, 327-348
   DOI 10.1007/978-1-0716-2095-3_14, PubMed 35507270
3. Flobak Å, Skånland SS, Hovig E, Taskén K, Russnes HG (2022)
   Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models
   Trends Pharmacol Sci, 43 (11), 973-985
   DOI 10.1016/j.tips.2022.08.009, PubMed 36163057
4. Giliberto M, Santana LM, Holien T, Misund K, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA, Coward E, Waage A, Taskén K, Skånland SS (2022)
   Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines
   Front Oncol, 12, 1040730
   DOI 10.3389/fonc.2022.1040730, PubMed 36523963
5. Giliberto M, Thimiri Govinda Raj DB, Cremaschi A, Skånland SS, Gade A, Tjønnfjord GE, Schjesvold F, Munthe LA, Taskén K (2022)
   Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically
   Mol Oncol, 16 (6), 1241-1258
   DOI 10.1002/1878-0261.13191, PubMed 35148457
6. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
   Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
   J Transl Med, 20 (1), 225
   DOI 10.1186/s12967-022-03432-5, PubMed 35568909
7. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
   Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
   J Transl Med, 20 (1), 317
   DOI 10.1186/s12967-022-03518-0, PubMed 35841045
8. Imbery JF, Heinzelbecker J, Jebsen JK, McGowan M, Myklebust C, Bottini N, Stanford SM, Skånland SS, Tveita A, Tjønnfjord GE, Munthe LA, Szodoray P, Nakken B (2022)
   T-helper cell regulation of CD45 phosphatase activity by galectin-1 and CD43 governs chronic lymphocytic leukaemia proliferation
   Br J Haematol, 198 (3), 556-573
   DOI 10.1111/bjh.18285, PubMed 35655388
9. Skånland SS, Inngjerdingen M, Bendiksen H, York J, Spetalen S, Munthe LA, Tjønnfjord GE (2022)
   Functional testing of relapsed chronic lymphocytic leukemia guides precision medicine and maps response and resistance mechanisms. An index case
   Haematologica, 107 (8), 1994-1998
   DOI 10.3324/haematol.2021.280393, PubMed 35236056
10. Skånland SS, Tjønnfjord GE (2022)
    Determining drug dose in the era of targeted therapies: playing it (un)safe?
    Blood Cancer J, 12 (8), 123
    DOI 10.1038/s41408-022-00720-7, PubMed 35999205
11. Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES, CONNECT Public–Private Partnership Consortium, Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R, InPreD-Norway and National Molecular Tumor Board Consortium, IMPRESS-Norway Consortium, Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å (2022)
    A national precision cancer medicine implementation initiative for Norway
    Nat Med, 28 (5), 885-887
    DOI 10.1038/s41591-022-01777-4, PubMed 35513529
12. Wei Q, Taskén K (2022)
    Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development
    Biochem J, 479 (20), 2219-2260
    DOI 10.1042/BCJ20210233, PubMed 36305711
13. Yin Y, Athanasiadis P, Karlsen L, Urban A, Xu H, Murali I, Fernandes SM, Arribas AJ, Hilli AK, Taskén K, Bertoni F, Mato AR, Normant E, Brown JR, Tjønnfjord GE, Aittokallio T, Skånland SS (2022)
    Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia
    Clin Cancer Res, 28 (20), 4444-4455
    DOI 10.1158/1078-0432.CCR-22-1221, PubMed 35998013

Publications 2021

1. Chellappa S, Kushekhar K, Hagness M, Horneland R, Taskén K, Aandahl EM (2021)
   The Presence of Activated T Cell Subsets prior to Transplantation Is Associated with Increased Rejection Risk in Pancreas Transplant Recipients
   J Immunol, 207 (10), 2501-2511
   DOI 10.4049/jimmunol.2001103, PubMed 34607938
2. Jenum S, Tonby K, Rueegg CS, Rühwald M, Kristiansen MP, Bang P, Olsen IC, Sellæg K, Røstad K, Mustafa T, Taskén K, Kvale D, Mortensen R, Dyrhol-Riise AM (2021)
   A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients
   Nat Commun, 12 (1), 6774
   DOI 10.1038/s41467-021-27029-6, PubMed 34811370
3. Jiang X, Bergquist A, Löscher BS, Venkatesh G, Mold JE, Holm K, Laerdahl JK, Skånland SS, Maleki KT, Cornillet M, Taskén K, Franke A, Karlsen TH, Björkström NK, Melum E (2021)
   A heterozygous germline CD100 mutation in a family with primary sclerosing cholangitis
   Sci Transl Med, 13 (582)
   DOI 10.1126/scitranslmed.abb0036, PubMed 33627483
4. Jøntvedt Jørgensen M, Nore KG, Aass HCD, Layre E, Nigou J, Mortensen R, Tasken K, Kvale D, Jenum S, Tonby K, Dyrhol-Riise AM (2021)
   Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients
   Front Cell Infect Microbiol, 11, 669623
   DOI 10.3389/fcimb.2021.669623, PubMed 34307194
5. Lone AM, Giansanti P, Jørgensen MJ, Gjerga E, Dugourd A, Scholten A, Saez-Rodriguez J, Heck AJR, Taskén K (2021)
   Systems approach reveals distinct and shared signaling networks of the four PGE₂ receptors in T cells
   Sci Signal, 14 (703), eabc8579
   DOI 10.1126/scisignal.abc8579, PubMed 34609894
6. Lone AM, Taskén K (2021)
   Phosphoproteomics-Based Characterization of Prostaglandin E₂ Signaling in T Cells
   Mol Pharmacol, 99 (5), 370-382
   DOI 10.1124/molpharm.120.000170, PubMed 33674363
7. Lorvik KB, Meyer-Myklestad MH, Kushekar K, Handeland C, Medhus AW, Lund-Iversen M, Stiksrud B, Kvale D, Dyrhol-Riise AM, Taskén K, Reikvam DH (2021)
   Enhanced Gut-Homing Dynamics and Pronounced Exhaustion of Mucosal and Blood CD4⁺ T Cells in HIV-Infected Immunological Non-Responders
   Front Immunol, 12, 744155
   DOI 10.3389/fimmu.2021.744155, PubMed 34691047
8. Melvold K, Giliberto M, Karlsen L, Ayuda-Durán P, Hanes R, Holien T, Enserink J, Brown JR, Tjønnfjord GE, Taskén K, Skånland SS (2021)
   Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies
   Mol Oncol, 16 (5), 1153-1170
   DOI 10.1002/1878-0261.13153, PubMed 34861096
9. Roeker LE, Eyre TA, Thompson MC, Lamanna N, Coltoff AR, Davids MS, Baker PO, Leslie L, Rogers KA, Allan JN, Cordoba R, Lopez-Garcia A, Antic D, Pagel JM, Martinez-Calle N, García-Marco JA, Hernández-Rivas JÁ, Miras F, Coombs CC, Österborg A, Hansson L, Seddon AN, López Jiménez J, Wilson MR, El-Sharkawi D et al. (2021)
   COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
   Blood, 138 (18), 1768-1773
   DOI 10.1182/blood.2021011841, PubMed 34297826
10. Skånland SS, Mato AR (2021)
    Overcoming resistance to targeted therapies in chronic lymphocytic leukemia
    Blood Adv, 5 (1), 334-343
    DOI 10.1182/bloodadvances.2020003423, PubMed 33570649
11. Yaqub S, Bjørnbeth BA, Angelsen JH, Fristrup CW, Grønbech JE, Hemmingsson O, Isaksson B, Juel IS, Larsen PN, Lindell G, Mortensen FV, Mortensen KE, Rizell M, Sandström P, Sandvik OM, Sparrelid E, Taflin H, Taskén K, ASAC study group (2021)
    Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): study protocol for a multicentre randomized placebo-controlled trial
    Trials, 22 (1), 642
    DOI 10.1186/s13063-021-05587-w, PubMed 34544470

Publications 2020

1. Caglayan S, Hashim A, Cieslar-Pobuda A, Jensen V, Behringer S, Talug B, Chu DT, Pecquet C, Rogne M, Brech A, Brorson SH, Nagelhus EA, Hannibal L, Boschi A, Taskén K, Staerk J (2020)
   Optic Atrophy 1 Controls Human Neuronal Development by Preventing Aberrant Nuclear DNA Methylation
   iScience, 23 (6), 101154
   DOI 10.1016/j.isci.2020.101154, PubMed 32450518
2. Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, Patel K, Osterborg A, Wojenski D, Kamdar M, Huntington SF, Davids MS, Brown JR, Antic D, Jacobs R, Ahn IE, Pu J, Isaac KM, Barr PM, Ujjani CS, Geyer MB, Berman E, Zelenetz AD, Malakhov N, Furman RR et al. (2020)
   Outcomes of COVID-19 in patients with CLL: a multicenter international experience
   Blood, 136 (10), 1134-1143
   DOI 10.1182/blood.2020006965, PubMed 32688395
3. Meås HZ, Haug M, Beckwith MS, Louet C, Ryan L, Hu Z, Landskron J, Nordbø SA, Taskén K, Yin H, Damås JK, Flo TH (2020)
   Sensing of HIV-1 by TLR8 activates human T cells and reverses latency
   Nat Commun, 11 (1), 147
   DOI 10.1038/s41467-019-13837-4, PubMed 31919342
4. Skånland SS, Karlsen L, Taskén K (2020)
   B cell signalling pathways-New targets for precision medicine in chronic lymphocytic leukaemia
   Scand J Immunol, 92 (5), e12931
   DOI 10.1111/sji.12931, PubMed 32640099

Publications 2019

1. Brennecke P, Rasina D, Aubi O, Herzog K, Landskron J, Cautain B, Vicente F, Quintana J, Mestres J, Stechmann B, Ellinger B, Brea J, Kolanowski JL, Pilarski R, Orzaez M, Pineda-Lucena A, Laraia L, Nami F, Zielenkiewicz P, Paruch K, Hansen E, von Kries JP, Neuenschwander M, Specker E, Bartunek P et al. (2019)
   EU-OPENSCREEN: A Novel Collaborative Approach to Facilitate Chemical Biology
   SLAS Discov, 24 (3), 398-413
   DOI 10.1177/2472555218816276, PubMed 30616481
2. Chellappa S, Kushekhar K, Munthe LA, Tjønnfjord GE, Aandahl EM, Okkenhaug K, Taskén K (2019)
   The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function
   J Immunol, 202 (5), 1397-1405
   DOI 10.4049/jimmunol.1701703, PubMed 30692213
3. Cremaschi A, Argiento R, Shoemaker K, Peterson C, Vannucci M (2019)
   Hierarchical Normalized Completely Random Measures for Robust Graphical Modeling
   Bayesian Anal, 14 (4), 1271-1301
   DOI 10.1214/19-ba1153, PubMed 32431780
4. Dukic AR, Gerbaud P, Guibourdenche J, Thiede B, Taskén K, Pidoux G (2019)
   Correction: Ezrin-anchored PKA phosphorylates serine 369 and 373 on connexin 43 to enhance gap junction assembly, communication, and cell fusion
   Biochem J, 476 (13), 1927
   DOI 10.1042/BCJ-2017-0529_COR, PubMed 31266855
5. Goodridge JP, Jacobs B, Saetersmoen ML, Clement D, Hammer Q, Clancy T, Skarpen E, Brech A, Landskron J, Grimm C, Pfefferle A, Meza-Zepeda L, Lorenz S, Wiiger MT, Louch WE, Ask EH, Liu LL, Oei VYS, Kjällquist U, Linnarsson S, Patel S, Taskén K, Stenmark H, Malmberg KJ (2019)
   Remodeling of secretory lysosomes during education tunes functional potential in NK cells
   Nat Commun, 10 (1), 514
   DOI 10.1038/s41467-019-08384-x, PubMed 30705279
6. Skånland SS, Cieślar-Pobuda A (2019)
   Off-label uses of drugs for depression
   Eur J Pharmacol, 865, 172732
   DOI 10.1016/j.ejphar.2019.172732, PubMed 31622593
7. Skånland SS, Cremaschi A, Bendiksen H, Hermansen JU, Thimiri Govinda Raj DB, Munthe LA, Tjønnfjord GE, Taskén K (2019)
   An in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL
   Leukemia, 34 (2), 478-487
   DOI 10.1038/s41375-019-0569-7, PubMed 31471562
8. Skånland SS, Taskén K (2019)
   Carboxyl-Terminal Src Kinase Binds CD28 upon Activation and Mutes Downstream Signaling
   J Immunol, 203 (4), 1055-1063
   DOI 10.4049/jimmunol.1801660, PubMed 31292214
9. Sukonina V, Ma H, Zhang W, Bartesaghi S, Subhash S, Heglind M, Foyn H, Betz MJ, Nilsson D, Lidell ME, Naumann J, Haufs-Brusberg S, Palmgren H, Mondal T, Beg M, Jedrychowski MP, Taskén K, Pfeifer A, Peng XR, Kanduri C, Enerbäck S (2019)
   FOXK1 and FOXK2 regulate aerobic glycolysis
   Nature, 566 (7743), 279-283
   DOI 10.1038/s41586-019-0900-5, PubMed 30700909

Publications 2018

1. Hermansen JU, Tjønnfjord GE, Munthe LA, Taskén K, Skånland SS (2018)
   Cryopreservation of primary B cells minimally influences their signaling responses
   Sci Rep, 8 (1), 17651
   DOI 10.1038/s41598-018-36121-9, PubMed 30518828
2. Rogne M, Chu DT, Küntziger TM, Mylonakou MN, Collas P, Tasken K (2018)
   OPA1-anchored PKA phosphorylates perilipin 1 on S522 and S497 in adipocytes differentiated from human adipose stem cells
   Mol Biol Cell, 29 (12), 1487-1501
   DOI 10.1091/mbc.E17-09-0538, PubMed 29688805
3. Schwab C, Gabrysch A, Olbrich P, Patiño V, Warnatz K, Wolff D, Hoshino A, Kobayashi M, Imai K, Takagi M, Dybedal I, Haddock JA, Sansom DM, Lucena JM, Seidl M, Schmitt-Graeff A, Reiser V, Emmerich F, Frede N, Bulashevska A, Salzer U, Schubert D, Hayakawa S, Okada S, Kanariou M et al. (2018)
   Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects
   J Allergy Clin Immunol, 142 (6), 1932-1946
   DOI 10.1016/j.jaci.2018.02.055, PubMed 29729943

Publications 2016

1. Curiel-Olmo S, García-Castaño A, Vidal R, Pisonero H, Varela I, León-Castillo A, Trillo E, González-Vela C, García-Diaz N, Almaraz C, Moreno T, Cereceda L, Madureira R, Martinez N, Ortiz-Romero P, Valdizán E, Piris MA, Vaqué JP (2016)
   Erratum: Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures
   Oncotarget, 7 (5), 6352
   DOI 10.18632/oncotarget.7118, PubMed 26997263

Publications 2010

1. Esaki Y, Li Y, Sakata D, Yao C, Segi-Nishida E, Matsuoka T, Fukuda K, Narumiya S (2010)
   Dual roles of PGE2-EP4 signaling in mouse experimental autoimmune encephalomyelitis
   Proc Natl Acad Sci U S A, 107 (27), 12233-8
   DOI 10.1073/pnas.0915112107, PubMed 20566843

Publications 2009

1. Huang H, Qiao R, Zhao D, Zhang T, Li Y, Yi F, Lai F, Hong J, Ding X, Yang Z, Zhang L, Du Q, Liang Z (2009)
   Profiling of mismatch discrimination in RNAi enabled rational design of allele-specific siRNAs
   Nucleic Acids Res, 37 (22), 7560-9
   DOI 10.1093/nar/gkp835, PubMed 19815667
2. Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, Kuroiwa K, Sugimoto Y, Narumiya S (2009)
   Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion
   Nat Med, 15 (6), 633-40
   DOI 10.1038/nm.1968, PubMed 19465928